Cover Image
市場調查報告書

Plexxikon Inc. : 產品平台分析

Plexxikon Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 256138
出版日期 內容資訊 英文 35 Pages
訂單完成後即時交付
價格
Back to Top
Plexxikon Inc. : 產品平台分析 Plexxikon Inc. - Product Pipeline Review - 2015
出版日期: 2015年07月22日 內容資訊: 英文 35 Pages
簡介

Plexxikon Inc. 是第一三共的美國子公司,致力於開發新的小分子治療藥。該公司的產品主要活用於腫瘤和中樞神經系統,代謝性疾病,心臟腎臟疾病,自體免疫,骨骼等領域。

本報告提供Plexxikon Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Plexxikon Inc.的基本資料

  • Plexxikon Inc.概要
  • 主要資訊
  • 企業資料

Plexxikon Inc. :R&D概要

  • 主要的治療範圍

Plexxikon Inc. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Plexxikon Inc. :開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 前臨床階段的產品/聯合治療模式

Plexxikon Inc.:藥物簡介

  • PLX-3397
  • PLX-8394
  • PLX-9486
  • PLX-7486
  • Small Molecules to Agonize PPAR for Multiple Sclerosis
  • Small Molecules to Inhibit FMS Kinase for Immunology, Gastrointestinal, Respiratory and Central Nervous Sytem Diseases

Plexxikon Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Plexxikon Inc.:最近的開發平台趨勢

Plexxikon Inc.:暫停中的計劃

Plexxikon Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
    • PLX-3397
    • PLX-3603
    • PLX-5622

Plexxikon Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07286CDB

Summary

Global Markets Direct's, 'Plexxikon Inc. - Product Pipeline Review - 2015', provides an overview of the Plexxikon Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Plexxikon Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Plexxikon Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Plexxikon Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Plexxikon Inc.'s pipeline products

Reasons to buy

  • Evaluate Plexxikon Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Plexxikon Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Plexxikon Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Plexxikon Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Plexxikon Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Plexxikon Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Plexxikon Inc. Snapshot
    • Plexxikon Inc. Overview
    • Key Information
    • Key Facts
  • Plexxikon Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Plexxikon Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Plexxikon Inc. - Pipeline Products Glance
    • Plexxikon Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Plexxikon Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Plexxikon Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Plexxikon Inc. - Drug Profiles
    • PLX-3397
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PLX-8394
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PLX-9486
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • PLX-7486
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Agonize PPAR for Multiple Sclerosis
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Small Molecules to Inhibit FMS Kinase for Immunology, Gastrointestinal, Respiratory and Central Nervous Sytem Diseases
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Plexxikon Inc. - Pipeline Analysis
    • Plexxikon Inc. - Pipeline Products by Target
    • Plexxikon Inc. - Pipeline Products by Route of Administration
    • Plexxikon Inc. - Pipeline Products by Molecule Type
    • Plexxikon Inc. - Pipeline Products by Mechanism of Action
  • Plexxikon Inc. - Recent Pipeline Updates
  • Plexxikon Inc. - Dormant Projects
  • Plexxikon Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • PLX-3397
      • PLX-3603
      • PLX-5622
  • Plexxikon Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Plexxikon Inc., Key Information
  • Plexxikon Inc., Key Facts
  • Plexxikon Inc. - Pipeline by Indication, 2015
  • Plexxikon Inc. - Pipeline by Stage of Development, 2015
  • Plexxikon Inc. - Monotherapy Products in Pipeline, 2015
  • Plexxikon Inc. - Out-Licensed Products in Pipeline, 2015
  • Plexxikon Inc. - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Plexxikon Inc. - Phase III, 2015
  • Plexxikon Inc. - Phase II, 2015
  • Plexxikon Inc. - Phase I, 2015
  • Plexxikon Inc. - Preclinical, 2015
  • Plexxikon Inc. - Pipeline by Target, 2015
  • Plexxikon Inc. - Pipeline by Route of Administration, 2015
  • Plexxikon Inc. - Pipeline by Molecule Type, 2015
  • Plexxikon Inc. - Pipeline Products by Mechanism of Action, 2015
  • Plexxikon Inc. - Recent Pipeline Updates, 2015
  • Plexxikon Inc. - Dormant Developmental Projects,2015
  • Plexxikon Inc. - Discontinued Pipeline Products, 2015

List of Figures

  • Plexxikon Inc. - Pipeline by Top 10 Indication, 2015
  • Plexxikon Inc. - Pipeline by Stage of Development, 2015
  • Plexxikon Inc. - Monotherapy Products in Pipeline, 2015
  • Plexxikon Inc. - Out-Licensed Products in Pipeline, 2015
  • Plexxikon Inc. - Pipeline by Top 10 Target, 2015
  • Plexxikon Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Plexxikon Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Plexxikon Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top